title: Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma.
abstract: We report results of RIC AHSCT in four adolescents with aggressive refractory HL. They all received three or four lines of therapy prior to RIC-AHSCT including autografts. At the time of RIC, they were in partial response except for one patient who had progressive chemoresistant disease. The conditioning regimen consisted of fludarabin, busulfan and ATG. They all had a matched related donor. The median follow-up was 12-16-month post-allograft. All patient transplants engrafted rapidly. The median time of hospitalization was 35 days. The median time to neutrophil recovery (>or=500/muL) was 19 days. All the patients were in complete donor chimerism at day 60. Four patients developed skin (grade <or= II) acute GvHD. All responded and all are alive. Two patients are in CR, one in PR and one relapsed six months after grafting after a PR. Each of the patients in PR received two DLI. These observations, together with the responses after DLI, suggest the presence of a graft vs. lymphoma effect in patients with advanced active HL. Prospective studies are needed to identify the patients likely to benefit most from this treatment approach.
authors.affiliation: Centre Hospitalier et Universitaire de Clermont-Ferrand, Service de Pédiatrie B et Unité Bioclinique de Thérapie Cellulaire, Clermont-Ferrand, France. cpaillard@chu-clermontferrand.fr
authors.forename: C
authors.initials: C
authors.lastname: Paillard
authors.forename: A
authors.initials: A
authors.lastname: Salmon
authors.forename: C
authors.initials: C
authors.lastname: Curtillet
authors.forename: A
authors.initials: A
authors.lastname: David
authors.forename: P
authors.initials: P
authors.lastname: Halle
authors.forename: F
authors.initials: F
authors.lastname: Cachin
authors.forename: P
authors.initials: P
authors.lastname: Bordigoni
authors.forename: G
authors.initials: G
authors.lastname: Michel
authors.forename: R
authors.initials: R
authors.lastname: Rousseau
authors.forename: E
authors.initials: E
authors.lastname: Dore
authors.forename: F
authors.initials: F
authors.lastname: Isfan
authors.forename: E
authors.initials: E
authors.lastname: Merlin
authors.forename: E
authors.initials: E
authors.lastname: Rochette
authors.forename: F
authors.initials: F
authors.lastname: Demeocq
authors.forename: J
authors.initials: J
authors.lastname: Kanold
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002066:Busulfan / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D008297:Male; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D012720:Severity of Illness Index; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine